Icon
+91 94997 68112
Login Register

Gocovri - (68.5mg; Capsule, Extended Release)

Amantadine ADAMAS Pharma
68.5mg; Capsule, Extended Release
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
Indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Yes
***** ****** ** *** ***** ** **** **** ** **** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, '*** *** *** *********. ** ****** **** **** ***** ****** ****** ** *** ****.
Gocovri Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15
***** ****** ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** ****** *** \ ********* *** **, **** ******* **** ** *** **, ****
  1. *** **, **** : * **** ** ** ***** *** ******* ** ******* *** *******
  2. **** **, **** : ***** ****** ******** ***** ****** ***** *** **** ** **** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, '***, ’***, ’***, ’***, *** ’***
  3. *** **, **** : ****** ****** * **** ******* ****** ** ******** ***** ** ********.
  4. *** *, **** : ****** ***** ***** ******* ********* ******* ****** ** *** ******
  5. *** *, **** : ****** ******* **** ******. ********* ** ********** ****** *** ****** ******* ** ***** *, ****, ** ******* ** ******* ************* ** **.
  6. *** **, **** : ****** ***** * **** ******* ***** ****** ** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, '***, ’***, ’***, ’***, *** ’***
  7. *** *, **** : *** *** ****** ******* ****** *** ***** **** ********* ******* ********* *** **** *** ******.

Gocovri - (137 mg Extended release, Capsule, Oral)

Amantadine ADAMAS Pharma
137 mg Extended release, Capsule, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
Less Than 5
None None
Indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Yes
****** ** *** ***** ** **** **** ** **** ******* ’***(*** **, ****), ’***(*** **, ****), ’***(*** **, ****), ’***(*** **, ****), ’***(*** **, ****), ’***(*** **, ****), ’***(*** **, ****), ’***(*** **, ****), ’***(*** *, ****), ’***(*** *, ****), ’***(*** *, ****), ’***(*** *, ****), *** ’*** (*** *, ****) *** *** ************ *********. ** ****** **** **** ****** ****** ** **** ****. *****, ****** ******* **** ******. ********* ** ********** ****** *** ****** ******* ** ***** *, ****, ** ******* ** ******* ************* ** **. ***** ****** ***** * **** ** **** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, '*** *** *** *********. ** ****** **** **** ***** ****** ****** ** *** ****.
Gocovri Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15
****** ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *******
***** ****** ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* ********* ********* ******* *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** *** \ ********* **** **, **** ******* **** ** ***** *, ****
***** ****** ** \ ** *** **, **** ******* ********* ******** ** ***** *, ****
  1. *** **, **** : * **** ** ** ***** *** ******* ** ******* *** *******
  2. *** **, **** : ****** ******** ***** ****** ***** *** **** ** **** ******* ’***(*** **, ****), ’***(*** **, ****), ’***(*** **, ****), ’***(*** **, ****), ’***(*** **, ****), ’***(*** **, ****), ’***(*** **, ****), ’***(*** **, ****), ’***(*** *, ****), ’***(*** *, ****), ’***(*** *, ****), ’***(*** *, ****), *** ’*** (*** *, ****).
  3. *** **, **** : ****** ****** * **** ******* ****** ** ******** ***** ** *** ******.
  4. *** *, **** : ****** ******* **** ******. ********* ** ********** ****** *** ****** ******* ** ***** *, ****, ** ******* ** ******* ************* ** **.
  5. *** **, **** : ***** ****** ******** ***** ****** ***** *** **** ** **** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, '***, ’***, ’***, ’***, *** ’***
  6. *** **, **** : ****** ***** * **** ******* ***** ****** ** ******* ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, ’***, '***, ’***, ’***, ’***, *** ’***
  7. *** *, **** : *** *** ****** ******* ****** *** ***** **** ********* ******* *********.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.